Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans ...

OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting ...

Briquilimab was well tolerated in the study. No SAEs or AEs grade 3 were reported. Furthermore, there were no reported AEs related to hair or skin color changes, hypersensitivity, or anemia. Mild ...

Today, Color Health announces the expansion of the nation's first fully integrated virtual cancer clinic. With this expansion ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th, 2025, including 180mg Q8W cohort Company to host conference call ...

The greater New York Metro region has one of the lowest organ donor registration rates in the country, leaving the decision up to family members for the large majority of donors. When entering a ...

Among the newer initiatives was developing the lab of the future; next-gen biology; AI and sustainability. The new facility ...

Corcept could be significantly undervalued based on long term potential growth and science-based innovation. Find out why ...

A recent Securities and Exchange Commission (SEC) filing listed Ms. Hahn’s spouse compensation at $4,337,928 for 2023 although this included stock options that may not yet have been awarded.

Find out what Sophie Hahn, Kate Harrison and Adena Ishii have to say about public safety, housing and their big ideas for ...

How does one manage to pull off a high-slit skirt during the peak of fall weather? It’s a question Cara Delevingne answered ...

ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to drive a functional cure for Hepatitis B, announced today that the com ...